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Background: The prevention of persistent human immunodeficiency virus type 1 (HIV-1) infection requires the
clarification of the mode of viral transduction into resting macrophages. Recently, DNA double-strand breaks (DSBs)
were shown to enhance infection by D64A virus, which has a defective integrase catalytic activity (IN-CA). However,
the mechanism by which DSBs upregulate viral transduction was unclear. Here we analyzed the roles of DSBs
during IN-CA–independent viral transduction into macrophages.
Results: We used cellular systems with rare-cutting endonucleases and found that D64A virus integrated efficiently
into the sites of artificially induced DSBs. This IN-CA-independent viral transduction was blocked by an inhibitor of
ataxia telangiectasia mutated protein (ATM) but was resistant to raltegravir (RAL), an inhibitor of integrase activity
during strand transfer. Moreover, Vpr, an accessory gene product of HIV-1, induced DSBs in resting macrophages
and significantly enhanced the rate of IN-CA-independent viral transduction into macrophages with concomitant
production of secondary viruses.
Conclusion: DSBs contribute to the IN-CA–independent viral infection of macrophages, which is resistant to RAL.
Thus, the ATM-dependent cellular pathway and Vpr-induced DNA damage are novel targets for preventing
persistent HIV-1 infection.
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The prognosis of individuals infected with human
immunodeficiency virus type 1 (HIV-1) has improved
due to the development of combination antiretroviral
therapy (cART) [1]. However, several lines of evidence
revealed that the current regimen does not block viral
replication completely [2], which promotes the emer-
gence of drug-resistant mutant viruses. Recently, new
anti-retroviral drugs that target viral entry or the inte-
gration of viral DNA into the host genome have been
applied clinically [3,4], which allows the possibility of
overcoming viruses that are resistant to conventional
cART. Moreover, an advanced study directed at the de-
velopment of novel anti-HIV-1 compounds attempted to
identify the cellular proteins that associate with HIV-1
proteins [5]. Macrophages are less sensitive to the toxic
effects of HIV-1 and they function as persistent producers* Correspondence: zakay@ri.ncgm.go.jp
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reproduction in any medium, provided the orof the virus [2]; therefore, it is important to develop novel
anti-HIV-1 compounds that target viral transduction into
resting macrophages.
Integrase, a 288-amino-acid and 32-kDa HIV-1 protein,
promotes strand-transfer reaction [6], where the reverse-
transcribed double-stranded viral DNA is integrated into
the host genome. The integrase catalytic activity (IN-CA)
excises two nucleotides from the 30-end of the viral DNA
and the CA-30-OH is ligated to the 50-O-phosphate end of
the genomic DNA [6]. All these strand transfer steps
depend on the presence of a D,D(35)E motif in the central
domain and any mutations in this motif abrogate the activ-
ity required for the strand-transfer process [7]. Notably,
single-strand gaps are produced in both regions flanking
the viral DNA and it was postulated that cellular factors
repair these gaps because viral proteins have a low DNA
damage repair activity [8].
Initially, Daniel et al. proposed that DNA-dependent
protein kinase was a cellular factor involved in gap-
repair [9], and then ataxia telangiectasia mutated (ATM),
ataxia telangiectasia and Rad3-related (ATR), Nijmegenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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polymerase 1 (PARP1) have also been nominated as
cellular proteins involved in efficient viral transduction
[10-13]. Using KU55933, a specific ATM inhibitor, Lau
et al. proposed that ATM is also involved in HIV-1
transduction [14], whereas Sakurai et al. demonstrated
that DNA damage repair enzymes are involved in multiple
steps of retroviral infection [15]. These observations
support the importance of DNA double-strand breaks
(DSBs) in viral transduction, although their roles are con-
troversial [16-19]. A possible explanation for discrepancies
in reported observations is that the single-strand gaps are
repaired in a redundant fashion by DNA damage repair
enzymes, the expression of which varies among cells [20]. It
is also possible that DSBs have modest effects on viral
transduction, which may be overwhelmed by the infectivity
of the wild-type (WT) virus. This suggests that it is import-
ant to evaluate the effects of DSBs using more sophisticated
experimental approaches.
Here we focused on the role of DNA damage (DSBs),
particularly in integration of viral DNA. Interestingly,
HIV-1 DNA integrated into artificially induced DSBs
in an IN-CA–independent manner and DNA damaging
agents upregulated the infectivity of IN-CA–defective
virus. The positive effects of DSBs on viral integration
were resistant to raltegravir (RAL), an IN-CA inhibitor.
Moreover, Vpr, an accessory gene product of HIV-1,
mimicked DNA damaging agents and increased IN-
CA–independent viral transduction into monocyte-
derived macrophages (MDMs). Even when the catalytic
activity of IN was impaired, infectious secondary virus was
generated without any mutations that yielded phenotypes
resistant to RAL.
Based on these observations, we propose that the
ATM-dependent mode of DSB-specific integration of
viral DNA and the Vpr-induced DSBs are novel targets
for anti-HIV compounds that inhibit viral transduction
into MDMs, a persistent reservoir of HIV-1 infection.Results
HIV-1 integrates into the sites of artificially induced DSBs
To understand the roles of DSBs in integration of viral
DNA into macrophages, we established a system using
THP-1 cells, a human monocytic leukemia cell line that
differentiates into macrophage-like cells after treatment
with phorbol myristate acetate (PMA) (Figure 1A) [21].
We transfected THP-1 cells with plasmid DNA that
contained the recognition sequence for I-SceI, a rare-
cutting endonuclease [22] and obtained clones with the
I-SceI site after drug selection. Using the experimental
procedures outlined in Figure 1A, the frequency of viral
DNA integration into I-SceI sites was evaluated. After
PMA-treated cells were infected with VSVG-pseudotypedWT virus (NL-Luc-E(−)R(−)) together with adenovirus-
expressing I-SceI, provirus DNA was detected in the
I-SceI provirus (Ad-I-SceI) site or its vicinity (Figure 1B,
Additional file 1: Figure S1A). PCR amplification targeting
the junction of the I-SceI site and the 50-end of the
integrated proviral DNA (Figure 1A) selectively generated
PCR amplicons from the Ad-I-SceI-infected samples
(compare the upper and lower panels of Figure 1B).
Sequence analysis of several independent clones detected
the presence of provirus DNA in the I-SceI site (Figure 1C,
each arrowhead indicates the integration site of individual
clones analyzed). Notably, KU55933 blocked I-SceI site-
targeted integration (Figure 1D, lower panel) [14].
Similar results were obtained using a different system
with another rare-cutting endonuclease, I-PpoI (Figures 1-
E–H and Additional file 1: Figure S1B). The recognition
sites of I-PpoI are present in the human genome, although
the mammalian genome has no gene that encodes the en-
zyme [23]. In this experiment, we used a lentiviral vector
to ensure the generality of our observations (Figure 1E).
As shown in Figure 1F, the viral DNA reproducibly
integrated into the I-PpoI site, which was confirmed
by PCR amplification and sequence analysis (Figure 1G
and H). The data clearly indicated that the viral DNA was
inserted in the DSB sites.Integration into DSB sites was independent of the
catalytic activity of integrase
Interestingly, analysis of the nucleotide sequence of the
viral DNA inserted in the I-SceI site revealed that both the
50- and 30-long terminal repeat (LTR) ends of the provirus
DNA had adenine and cytidine (pAC) dinucleotides
(Figure 1I) [6], suggesting that the viral DNA integrated
into DSBs in an IN-CA–independent manner (Additional
file 1: Figure S2). To confirm this, similar experiments
were performed using D64A mutant virus, which is de-
fective in integrase, co-infected with Ad-I-SceI (Figure 2A).
PCR amplification followed by sequence analysis consist-
ently detected the presence of pAC in the 50 ends of the
integrated viral LTR (Figure 2B).
We then estimated the frequency of viral integration
into the DSB sites in the total number of provirus DNA.
Intriguingly, we observed that more than half of the
integrated D64V lentiviruses were present in the I-PpoI
site (approximately 53%) when viral infection was
conducted using HT1080 cells that had been cultured in
0.1% FBS (Figure 2C, Additional file 1: Figure S3A). In
contrast, the DSB-specific integration of the viral DNA
was reduced to approximately 18% in a similar experi-
ment performed in the presence of 10% FBS. FACS ana-
lysis of HT1080 cells that had been pulse-labeled with
BrdU revealed that the population of cycling cells
decreased from 43% to 18% when cells were cultured in
Figure 1 HIV-1 DNA integrates into a DSB site. (A) An experimental procedures for (B)–(D) and (I). Red arrows indicate the primers used in (B)
and (D). (B) PCR amplification of WT provirus DNA integrated in the I-SceI site. Each lane depicts each result of twelve samples independently
infected with WT virus and Ad-I-SceI (upper panel) or Ad-LacZ (lower panel). M, molecular marker. (C) Upper panel, representative sequencing
chromatogram of the PCR amplicon in samples, which were shown in upper panel of (B). Lower panel, summary of viral DNA integration sites.
The 18-bp recognition sequence of the I-SceI site is shown. When digested with I-SceI, a 30-protruding end of 4 nucleotides is formed (dotted red
line). Each arrowhead indicates an actual integration site of viral DNA in samples shown in (B). Integration sites were identified on most of clones
except for two clones, which are indicated by arrowheads with a horizontal bar. (D) Effect of KU55933 on viral DNA integration into the I-SceI site.
(E) Schematic outline of the I-PpoI-PCR experimental design in (F)–(H) (Top panel). The lentiviral vector was used in this study (bottom panel). (F)
PCR amplification of lentiviral vector inserted in the I-PpoI site. Primers are shown by red arrows (G) A representative result of sequence analysis
of proviral DNA integrated in the I-PpoI site. (H) Summary of integration sites of the lentiviral vector. Each arrowhead depicts each result of
independent clones. The dotted line indicates I-PpoI site with a 30-protruding end of 4 nucleotides. (I) Summary of the I-SceI-PCR sequence data.
A representative nucleotide sequence was shown at the top of each panel. Asterisks indicate the pAC that would be normally removed during
IN-mediated integration (see Additional file 1: Figure S2). Dots indicate identical sequence to that of the representative sequence. Dashes indicate
deleted nucleotides.
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Figure 2 Frequent integration of the IN-CA defective virus into
the DSB site. (A) PCR amplification of provirus DNA integrated into
the I-SceI site after infection of WT virus (left) or NL-Luc-IN-D64A-E(−)
R(−) virus (D64A virus) (right). PMA-treated THP-1/I-SceI cells were
used. Each lane shows an independent result that was obtained
from cells cultured in a single well of 6-multiwell. For each test
group, six wells were independently infected with viruses. M,
molecular marker. Arrowheads indicate amplicons of viral DNA
integrated in the I-SceI site, which was further confirmed by
sequence analysis. (B) Sequence data of D64A provirus DNA that
was integrated in the I-SceI site. A representative result is shown at
the top. Asterisks indicate the pAC. Dots indicate identical
nucleotides to those of the representative sequence. Dashes indicate
deleted nucleotides. (C) Experimental protocol for evaluating the
frequency of viral integration into the DSB site. I-PpoI-qPCR and
EGFP-qPCR analyses were done for quantification of I-PpoI site-
specific and total proviral DNA copy numbers, respectively.
Representative data of two independent experiments was shown.
Error bars, s.d. of triplicate assays. (D) Evaluation of I-SceI site-
targeting efficiency. PMA-treated THP-1/I-SceI cells were infected
with WT or D64A virus for 2 h, and cells were harvested 48 hpi for
the I-SceI-qPCR analysis (see Methods section). To cleave the I-SceI
site, cells were infected with the Ad-I-SceI at an MOI of 100 from 1 h
post HIV-1 infection. Treatment with RAL and KU55933 was
conducted from −2 h to 48 hpi. Effects of RAL and KU55933 were
evaluated on 11 samples that were prepared from three
independent experiments. Each dot indicates copy numbers of
provirus DNA that had integrated in the I-SceI site in 103 cells, which
were infected as a single test sample.
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Figure S3B). The data indicated that the cellular conditions
had a large influence on the rate of viral integration into
DSB sites. Of note, no remarkable integration of WT virus
into the DSB site was detected under any conditions of cell
culture with different concentrations of FBS (Figure 2C).
These data suggested that the IN-CA–defective virus was
the main target of capture by the DSB sites.
To accurately determine the exact rate of DSB-specific
integration of viral DNA, we developed a system for
quantitative I-SceI-PCR (I-SceI-qPCR) analysis of the
provirus DNA and investigated whether viral DNA
integration into the I-SceI site was influenced by RAL
(see experimental procedures in Methods section). As
shown in Figure 2D, RAL did not attenuate the DSB-
specific integration of WT viruses in PMA-treated THP-1
cells (a single dot indicates each result of 11 samples in
three independent experimental groups). In contrast,
KU55933 efficiently blocked the DSB-specific integration
of WT and D64A viruses (Figure 2D). These data suggest
that capture of viral DNA in the DSB sites was selectively
induced in an IN-CA–independent manner, which was
ATM-dependent.
DNA damaging agents upregulate IN-CA–independent
viral integration
Next, we examined the effects of the DNA damaging
agents etoposide and bleomycin on viral infection. As
shown in Figure 3A, both compounds increased the
infectivity of D64A virus in all cells examined, which
included MDMs and various human cell lines. However,
the positive effects of these compounds were not con-
sistently observed in WT virus, although they ectopically
enhanced the frequency of viral transduction (Figure 3B,
Additional file 1, Figure S4), i.e., etoposide enhanced the
infectivity of WT virus in serum-starved HT1080 cells
and nocodazole-treated human primary fibroblasts (TIG-3)
(Figure 3B, upper panels, Additional file 1, Figure S4) [24].
However, it had no positive effects when cells were cultured
in the presence of 10% FBS (Figure 3B, upper panels,
Additional file 1, Figure S4). In addition, bleomycin had no
positive effects on the infectivity of WT virus under any
culture conditions (Figure 3B, lower panels, Additional
file 1, Figure S4). These data indicate that the effects of
DNA damage on viral transduction are only observable
when combined with the IN-CA–defective virus, or they
are obscured by the infectivity of the WT virus.
DSBs enhanced viral transduction at the integration step
of viral infection
We quantified the integrated DNA copy numbers to clarify
the roles of DSBs in IN-CA–independent viral transduc-
tion in greater detail. We used serum-starved HT1080 cells
to minimize the possible effects of DSBs generated
Figure 3 DNA damage enhances the IN-CA independent infectivity of HIV-1. Cells were infected with D64A (A) or WT (B) viruses in the
presence of etoposide or bleomycin from 0–48 h post-infection (hpi). After 48 h, cell extracts were prepared and subjected to the luciferase assay.
The fold increase of the activity after each viral infection with or without DNA damaging agents was shown. In experiments using cell lines,
representative data from one of repeated experiments was shown. Results are presented as mean ± s.d. of triplicate assays. All cells except for
MT-4 cells were treated with 0, 0.625, 1.25, 2.5, 5, 10 μM etoposide or 0, 1.25, 2.5, 5, 10, 20 μM bleomycin. MT-4 cells were treated with 0, 0.039,
0.078, 0.156, 0.313, 0.625 μM etoposide or 0, 0.078, 0.156, 0.313, 0.625, 1.25 μM bleomycin. Raw data of luciferase activity was shown in Additional
file 1: Figure S4. *, P < 0.05; **, P < 0.01.
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PCR (qPCR)-based assay demonstrated that treatment with
1.25–20 μM etoposide or bleomycin significantly increased
the number of integrated viral DNA copies (Figure 4A).
We performed a colony formation assay to further demon-
strate the effects of DNA damaging agents on viral trans-
duction. As shown in Figure 4B, treatment with DNA
damaging agents significantly increased the number of
drug-resistant colonies, indicating that DSBs promoted the
integration of D64A virus (Figure 4B). In contrast, these
compounds had no obvious effects on the integration of
WT virus (Figure 4C and D). Although it has been
reported that DSBs augment viral replication during
multiple steps [15], our observations suggested that they
enhance the integration step of viral DNA, which is a
pivotal step in viral transduction.
DSB-dependent viral integration induced minor structural
alterations in provirus DNA but generated infectious
progeny viruses
It has been proposed that a non-homologous end-
joining (NHEJ) pathway is involved in the repair of thegaps formed during viral integration [25] and that the
DSB-specific integration of provirus DNA is susceptible
to structural alterations [26]. To evaluate this, we quan-
tified the frequency of structural modifications with
provirus DNA using linear amplification mediated-PCR
(LAM-PCR), followed by nucleotide sequence analysis
[27]. When cells were infected with the virus in the
presence of RAL, insertions and deletions in the 50-LTR
region were detected in 70.6% and 35.3% of cells,
respectively (Table 1). In contrast, only 5% of the integrants
were positive for structural alterations when infected in the
presence of dimethyl sulfoxide (DMSO, solvent control)
(Table 1 and Additional file 1: Figure S5). The data
implicated that viral integration in the presence of RAL is
susceptible to disruption of provirus DNA structures,
which abrogated the production of secondary viruses.
To clarify this possibility, we investigated the effects of
RAL on single-round viral infection using several cell
lines. As shown in Figure 5A, we found that the infectiv-
ity of the WT virus was significantly attenuated by RAL,
i.e., viral infection was reduced to 0.2% and 3.8% when
10 μM RAL was used to treat MAGIC5 cells and MT-4
Figure 4 DNA damage enhances the integration rate of HIV-1. Serum-starved HT1080 cells were infected with D64A (A) or WT (C) viruses in
the presence of etoposide or bleomycin from 0–24 hpi. After 48 h, genomic DNA was extracted and subjected to qPCR. Relative copy numbers
of HIV-1 DNA to β-globin were estimated (top) and the fold increase of HIV-1 DNA copy number compared to control infection that was
conducted without DNA damaging agents (bottom) were calculated. For colony formation assay, VSVG-pseudotyped D64A (NL-Neo-IN-D64A-E(−)
R(−)) (B) or WT (NL-Neo-E(−)R(−)) (D) viruses, which had the neomycin resistant gene (NeoR), were used. HT1080 cells were treated with various
doses of etoposide or bleomycin for 24 h, which were added at the same time of viral infection. After selection with 600 μg/mL of G418,
numbers of NeoR colonies were counted. Numbers of NeoR colonies were normalized by plating efficiency. Error bars, s.d. of triplicate assays.
*P < 0.05; **P < 0.01.
Koyama et al. Retrovirology 2013, 10:21 Page 6 of 18
http://www.retrovirology.com/content/10/1/21cells, respectively. However, these values were the same
with D64A virus, which suggests that restricting IN-CA
could not block viral infection completely. This suggestion
was supported by tests using azidothymidine (AZT, an RT
inhibitor), which further blocked the infectivity of D64A
virus. Importantly, the same results were obtained using
elvitegravir (EVG, another IN-strand transfer inhibitor) in
PMA-treated THP-1 cells (Figure 5A).
These observations strongly suggest that the WT
virus can replicate in the presence of RAL, although the
potential for viral replication is low and at similar level to
IN-CA–defective virus. To test this possibility, we infectedMT-4 cells with a replication-competent virus in the pres-
ence of RAL and examined the production of the progeny
virus using MAGIC5 cells (HeLa/CD4, CCR5, LTR-β-gal)
[28]. As shown in Figure 5B, we observed viral replication
with the WT virus, although RAL was continuously added
in the culture medium (one representative result from
three independent experiments is shown with other
experimental data in Additional file 1: Figure S6A). To
exclude the possibility that the secondary virus possessed
mutations that could overcome the inhibitory effects of
RAL, we tested the viral RNA recovered from the culture
supernatants. Analysis of the nucleotide sequences of 10
Table 1 HIV-1 DNA integration sites and host-virus junction sequence
Seq ID Inhibitor Chr Locus Strand RefSeq gene Insertion Deletion
100902 DMSO 20 33371451 plus NCOA6 - -
100903 DMSO 17 35993714 minus DDX52 - -
100904 DMSO 3 156651874 minus LEKR1 - -
100906 DMSO 20 60900963 minus LAMA5 - -
100907 DMSO 3 19680267 minus DLG1 - -
100910 DMSO 4 150767744 plus - - -
100912 DMSO 9 131400460 plus WDR34 - -
100914 DMSO 1 156020423 minus UBQLN4 11bp (ACAGCAGTTAG) 37 bp
100916 DMSO 17 43551920 minus PLEKHM1 - -
100919 DMSO 20 2467413 minus ZNF343 - -
100921 DMSO 10 114725221 minus TCF7L2 - -
106501 DMSO 4 87017147 plus MAPK10 - -
106502 DMSO 2 98458616 minus TMEM131 - -
106505 DMSO 15 44399565 minus FRMD10 - -
106506 DMSO 2 197544261 plus CCDC150 - -
106510 DMSO 7 333212296 minus BBS9 - -
106513 DMSO 2 230499770 plus DNER - -
106520 DMSO 17 38682989 plus CR597260 - -
106521 DMSO 19 17213409 minus MY09B - -
106524 DMSO 6 33219360 plus VPS52 - -
100925 RAL 9 33033919 plus DNAJA1 - 9 bp
100931 RAL 14 44024820 minus - - 20 bp
100937 RAL 2 102387409 plus MAP4K4 9 bp (GACACTTAG0 -
100940 RAL 5 176735496 plus MXD3 2 bp (AC) -
100944 RAL 3 105267040 plus - 21 bp (AATAAAAAGGTACAAATAGAC) -
106525 RAL 14 87606685 minus - 6 bp (TCATAA) 3 bp
106530 RAL 22 36006496 plus MB 1 bp (A) 9 bp
106534 RAL 7 130544996 minus CR618431 10 bp (TTGTAATTAC) -
106537 RAL 1 63779999 minus BC040309 16 bp (AAAGAAAAGGGGGGAC) -
106538 RAL 3 190624485 minus - - 4 bp
106540 RAL 3 85084717 minus CADM2 - -
106542 RAL 18 40381428 minus RIT2 2 bp (CA) 1 bp
106558 RAL 6 52427867 minus TRAM2 - -
106574 RAL 9 18460635 plus - 9 bp (ACACCTAAT) -
106582 RAL 1 6482403 minus HES2 4 bp (GGAC) -
106588 RAL 11 28954901 plus - 4 bp (GGAC) -
106596 RAL 7 92394729 plus CDK6 4 bp (GGAC) -
HIV-1 DNA integratio sites were determined by LAM-PCR. LAM-PCR sequence were aligned to the human genome reference (GRCh37/hg19, Feb. 2009, UCSC).
Chr, chromosome.
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mutations related to RAL-resistant phenotypes (Table 2,
Additional file 1, Table S1 and Figure S7) [29-32]. A simi-
lar experiment was performed using D64A virus. Again,
we observed reproducible viral replication in the pres-
ence or absence of RAL (Figure 5C, Additional file 1:Figure S6B). Analysis of the nucleotide sequence of the
progeny virus RNA revealed that a single clone of the 10
viruses analyzed was positive for a reported mutation linked
to a RAL-resistant phenotype (M154I in Table 2, Additional
file 1, Table S1). However, the other nine clones were free
of such mutations. In addition, no WT virus revertants
Figure 5 IN-CA deficient virus can produce infectious progeny virus. (A) Effect of RAL on the infectivity of WT and D64A viruses. After
infection with VSVG-pseudotyped WT (NL-Luc-E(−)) or D64A (NL-Luc-IN-D64A-E(−)) virus in the presence of AZT, RAL or EVG, cells were harvested
at 48 hpi and subjected to luciferase assay. Relative luciferase activity compared to a control sample, in which WT virus was infected without any
compounds, were plotted. Concentration of AZT was 0, 1, 10 and 100 μM, whereas concentrations of RAL and EVG were 0, 0.1, 1 and 10 μM.
Black circles, WT virus; gray circles, D64A virus; ND, not detected. Representative data of two independent experiments was shown. Error bars, s.d.
of triplicate assays. (B) Functional evaluation of progeny viruses generated after IN-CA independent infection. MT-4 cells were infected in the
presence of RAL with replication-competent WT virus (NL4-3). Then conditioned medium was harvested every 2 d, and infectivity of progeny
virus present in the conditioned medium was evaluated using MAGIC5 cells. (C) Similar experiment with (B) was done using D64A (NL-IN-D64A)
virus. Representative results of three independent experiments are shown. (D) Secondary virus generated from MDMs infected with virus in the
presence of RAL. MDMs were infected with a replication-competent NL4-3 virus with an env gene, which was derived from R5-tropic ADA virus
(NL-ADA-R(−)). Then, HIV-1 RNA copy number in the conditioned medium was quantified by RT-qPCR analysis. To evaluate effects of DNA
damaging agents, 2.5 μM etoposide or 1.25 μM bleomycin were added from 0–2 dpi. To exclude the possibility that carry-over virions, which
were remnant viruses that could not be completely removed after the initial infection, we included control sample, in which a fusion inhibitor
enfuvirtide (ENF) was continuously added from 0 dpi to the end of assay.
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infected with human T cell leukemia virus, expresses Tax,
a viral protein. One possible explanation for the efficient
IN-CA independent viral infection is due to DNA damage
that is induced by the biological activity of Tax [33,34].
After establishing that RAL-resistant viral replication
could be induced in MT-4 cells, we investigated whetherthe same mode of viral infection can occur in MDMs.
We detected no apparent replication of infectious
secondary virus in MDMs, which were infected in the
presence of RAL. However, viral replication was detected
when DNA damaging agents were treated at the same
time as the viral infection (Figure 5D). Importantly,
the addition of enfuvirtide (ENF), a fusion inhibitor,
Table 2 IN mutations of NL-ADA or NL-IN-D64A-ADA











#2 A144G E48E (Silent)










#5 A191C, A772G D64A, K258E
#6 A191C, U842A D64A, V281E
#8 A38G, A191C, G462A E13G, D64A, M154I
#10 A191C, A279, A809G D64A, T93T (Silent),
D270G




#2 A191C, G806C D64A, R269T
#3 A191C, A718G D64A, K240E
#5 A191C, G829U D64A, G277C
#6 A191C, U598C D54A, I200T
#9 A191C, G462A D64A, M154I
#7 G7A, G39A, G103A,
A191C
D3N, E13E (Silent), E35K,
D64A
Nucleotide sequence of progeny viral RNA was analyzed. In two of 20 clones
examined, we identified M1541, which was reported as a mutation related to
RAL-resistant phenotype [30].
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which indicated that the detected virus was not a
remnant of the initially infected virus and that it was a
progeny virus. Similar results were obtained in inde-
pendent experiments using MDMs prepared from a dif-
ferent donor. These data and the absence of reported
mutations in these viral RNA showed that DSBs
promoted productive viral transduction even in the pres-
ence of RAL.Based on these experiments, we expected that DSB
site may capture and incorporate virus DNA as a struc-
turally intact form. To obtain direct evidence for
this possibility, we analyzed the nucleotide sequences
of the provirus DNA integrated in the DSB site. In
these experiments, serum-starved HT1080 cells were
co-infected with an Ad-I-PpoI and an IN-defective
lentiviral vector (Lenti6-EGFP-D64V), which contained a
blasticidin-resistant gene. After infection, the blasticidin-
resistant cells were selected and cloned, and the lentivirus-
infected cell clones were screened using I-PpoI-qPCR. We
isolated a total of 74 clones and obtained 10 (13.5%), five
(6.8%), and five (6.8%) clones, which contained proviral
DNA at the I-PpoI site in direct, inverted, or both direct
and inverted orientations, respectively (Figure 6A). Of
these, five clones were EGFP-positive (Figure 6B) and the
proviral DNA was integrated only into the I-PpoI site in
one of these clones (Figure 6C, D, clone #2413). This was
further confirmed by fluorescent in situ hybridization
(FISH) analysis, which detected provirus DNA in a single
locus in the genome (Figure 6E). Sequence analysis of the
provirus DNA of clone #2413 finally identified an intact
viral DNA structure with the flanking nucleotide sequence
of the I-PpoI site (Figure 6F). The data indicated clearly
that the structurally intact viral DNA could integrate into
the DSB site.
Vpr mimicked DSBs and enhanced the
IN-CA–independent viral transduction into resting
macrophages
Vpr, an accessory gene of HIV-1, encodes a 96-amino
acid virion-associated nuclear protein with pleiotropic
activities, including a cell cycle abnormality during the
G2/M phase, enhanced promoter activity and apoptosis.
It has also been proposed that Vpr is important for
macrophage infection through the nuclear trafficking of
a preintegration complex [35]. Previously, it has been
reported that Vpr elicits cellular signals triggered by
DNA damage [36-40], which suggests that Vpr promotes
IN-CA–independent viral transduction. To test this
hypothesis, we checked whether infection with R+
virus induced the DNA damage response in MDMs
(Figure 7A). In agreement with our previous observations,
infection with R+ virus evoked the cellular response
triggered by DNA damage [36,37,41,42]. We investigated
the infectivity of R+ virus and observed that Vpr enhanced
viral transduction in the presence of RAL, which was
blocked by AZT (Figure 7B). Similar to the effect of DSBs,
Vpr enhanced the viral infectivity during the integration
step (Figure 7C). Moreover, Vpr enhanced the infection of
MDMs by D64A virus (Figure 7D and Additional file 1:
Figure S8).
To further elucidate the effects of Vpr on the infection of















































































































































Figure 6 (See legend on next page.)
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Figure 6 Detection of intact provirus DNA in the DSB site. (A) I-PpoI-qPCR screening of cell clones containing provirus DNA in I-PpoI site.
HT1080 cells were infected with Ad-I-PpoI at an MOI of 30 in the medium with 0.1% FBS. After 24 h, cells were further infected with lentiviruses
(VSVG-pseudotyped Lenti6-EGFP-D64V) also under serum-starved conditions. Two h later, medium was changed with fresh one with 0.1% FBS. On
the next day, medium was replaced with a complete medium with 10% FBS. Blasticidin-resistant colonies were isolated and I-PpoI site targeting
provirus was detected by I-PpoI-qPCR. The threshold of detecting provirus integrated as direct or inverted repeat orientation was −1 log(10)
copies/cell (indicated in red horizontal lines). (B) EGFP expression analysis. Cells containing the proviral DNA in I-PpoI site in (A) were further
analyzed for the expression of EGFP by flow cytometer. (C) The estimation of proviral DNA copy number. Copy numbers of provirus DNA in
EGFP-positive clones, shown in (B), were analyzed by Southern blot by using a part of DNA fragment of the lentiviral vector as a probe. Genomic
DNA extracted from each clone was digested with BamHI or EcoRI prior to electrophoresis. Restriction maps are shown (right panel). B, BamHI; E,
EcoRI; P, I-PpoI. Of note, clone #2413 possessed a single copy of provirus DNA. (D) Sequence analysis of lentiviral vector integrated in the I-PpoI
site. EGFP-positive clones shown in (B) were subjected to sequence analysis. I-PpoI-PCR amplicons were directly used as a template for sequence
analysis. (E) FISH analysis of the #2413 clone. (F) Nucleotide sequence of intact proviral DNA present in the DSB site. The proviral DNA of #2413
clone was sequenced and whole nucleotide sequence data was shown. In #2413 clone, no structural alternations of provirus DNA were detected.
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and human cell lines by calculating the fold-increase in
the luciferase activity, which reflected the infectivity of
each virus (Figure 7E, Additional file 1, Figure S9). As
summarized in Figure 7F, the positive effects of Vpr were
the most striking when MDMs were infected with D64A
virus (D64A/R+ virus). The infectivity of D64A/R+ virus in
MDMs was 37.0–265.1-fold higher than that of D64A/R−
virus. In contrast, these positive effects were not detected
with the WT/R+ virus. Moreover, the positive effects of
Vpr were less conspicuous in PBMCs, consistent with pre-
vious observations that Vpr functions as a positive factor
during viral transduction into MDMs [43]. Combined with
previous reports that Vpr activates ATM [36,37] and ATR
[38], our observations suggest that the enhanced infectivity
of D64A/R+ virus in MDMs is attributable to Vpr-induced
DSBs [36,37].
Discussion
Since it was first postulated that the cellular proteins
responsible for DNA damage repair are positively
involved in HIV-1 infection [9], roles of DSBs and DNA
damage repair enzymes in viral infection have remained
controversial [10-14,16-19,44]. However, several lines of
evidence have suggested that DSBs have at least two
roles in viral infectivity, i.e., direct upregulation of the
rate of viral DNA integration into the host genome and
the activation of DNA damage repair enzymes, which
contribute to multiple steps in HIV-1 infection including
repair of the gaps formed during the integration of viral
DNA into the host genome [15]. Here we focused on the
first possibility and provided experimental data, which
showed that DNA damage increased the frequency of
viral integration into the host genome.
In particular, we found that DSBs promoted the trans-
duction of D64A virus, which was defective with respect
to the catalytic activity of integrase (IN-CA). Moreover,
DSBs upregulated the infectivity of WT virus by
overcoming the inhibitory effects of RAL, an IN-CA in-
hibitor. Furthermore, infectious secondary viruses weregenerated from the provirus DNA formed through IN-
CA–independent viral transduction. Our observations
were highly consistent with previous reports that the
IN-CA–defective virus can integrate into the host gen-
ome [45-47]. Ebina et al. reported that the integration
rate of the IN-CA–defective virus was enhanced by
DNA damaging agents such as x-ray irradiation or
hydrogen peroxide [48], whereas we showed that DSBs
upregulated IN-CA–independent viral integration and
promoted the production of secondary viruses, which
were competent for subsequent viral infection. Importantly,
analysis of the nucleotide sequences of the viral RNA from
the secondary viruses showed that there were no revertants
to WT virus. Most of the viruses analyzed also had no
reported mutations linked to RAL-resistant phenotypes
[29-32]. Taken together with observation that RAL could
reduce the infectivity of WT virus at a similar level to
D64A virus, our data also suggest that currently available
IN inhibitors cannot completely block productive viral in-
fection, which is possibly enhanced by DSBs.
The mechanism of DSB-induced upregulation of viral
transduction remains elusive but our data suggest that DSB
sites provide a platform where viral DNA integrates in an
IN-CA–independent manner. When cells were co-infected
with HIV-1 virus and an adenovirus that expressed rare-
cutting endonucleases such as I-SceI or I-PpoI, we reprodu-
cibly observed that the viral DNA was integrated into the
corresponding DSB sites. However, interestingly, DSB-site
specific viral integration was influenced by viral and
cellular factors. First, we observed that targeting of
viral DNA to the DSB site was observed mainly during IN-
CA–independent viral transduction, although its frequency
was low compared with WT virus. Second, it was
influenced by the cellular conditions of the target cells, i.e.,
the frequency of IN-CA-independent viral transduction
into DSB sites decreased from approximately 53% to 18%
when the concentration of FBS was changed from 0.1% to
10% (Figure 2C). These results and the FACS analysis sug-
gest that this difference may be because the spontaneous


















































WT R– WT R+ D64A R– D64A R+E
F
 0.1




























































NDND ND ND NDND NDND NDND ND











































2 4 6 8 10 12 14 16
(dpi)






















– + – + – + – + Vpr









– + – + – + – +
























































Figure 7 Vpr mimics DNA damaging agents, and enhances the
IN-CA independent macrophage infection. (A) Vpr induces DNA
damage cellular signals in MDMs. HT1080 cells or MDMs were
infected with VSVG-pseudotyped R– virus (NL-Luc-E(−)R(−)) or R+
virus (NL-Luc-E(−)), and then analyzed immunochemically. Bars = 10 μm.
(B) Effect of RAL on the infectivity of WT and D64A viruses. MDMs were
infected with WT or D64A viruses in the presence of AZT or RAL. The
cells were harvested at 48 hpi and subjected to luciferase assay. Relative
luciferase activity values to WT R– infectivity are shown. Black circles, WT;
gray circles, D64A; ND, not detected. Error bars, s.d. of triplicate assays.
(C) Effects of Vpr on the integration of viral DNA into the host genome.
Serum-starved HT1080 cells were infected with VSVG-pseudotyped IN
WT or D64A mutant virus with or without Vpr. After 48 h, infected cells
were subjected to qPCR analysis. Error bars, s.d. of triplicate assays.
*P < 0.05. (D) HIV-1 replicates in MDMs in the presence of RAL.
Replication-competent NL4-3 with an intact env gene derived from
R5-tropic ADA viruses (NL-ADA, NL-ADA-R(−), NL-ADA-IN-D64A, and NL-
ADA-IN-D64A-R(−)) were infected. Then, copy numbers of HIV-1 RNA in
the conditioned medium was quantified by RT-qPCR. E and F) Positive
effects of Vpr on infection of D64A virus into MDMs. Primary cells and
cell lines were infected with IN WT or D64A mutant virus with or without
Vpr. Cells were harvested at 48 hpi and subjected to luciferase assay.
(E) Relative luciferase activity values to WT R– infectivity are shown. White
bars, WT/R–; light gray bars, WT/R+; dark gray bars, D64A/R–; black bars,
D64A/R+. Error bars, s.d. of triplicate assays. (F) Fold increase of
R+ virus infectivity to R– virus. White bars, WT; black bars, D64A.
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viral integration into artificially induced DSBs.
Interestingly, the DSB-specific integration of DNA
fragments has been reported for hepatitis B virus DNA, an
adeno-associated viral vector (AAV) [49,50], and Ty1 [51],
a DNA retrotransposon of Saccharomyces cerevisiae. These
observations suggest that the DSB site-specific integration
of exogenous DNA fragments is not lentivirus-specific,
which also indicates that DSB site-specific integration
is dependent on the cellular response to DNA damage.
We observed that KU55933, a specific ATM inhibitor,
consistently blocked DSB-specific viral integration
(Figures 1D and 2D). Interestingly, x-ray irradiation triggers
the retrotransposition of long interspersed element 1 in
human cells, which is also dependent on ATM [52],
implying that a conserved cellular response to DNA
damage is functionally involved in the capture of viral
DNA in the DSB site.
We detected minor nucleotide deletions of approxi-
mately <9 bp in five of six clones of the provirus DNA,
which were derived from cells infected with virus in the
presence of RAL (Table 1). Such structural alternations
would be due to the NHEJ repair system that is involved
in viral integration in the presence of RAL. Because it
has been reported that provirus DNA with 10-bp
deletions from nucleotides +3 to +12 in the 50-LTR
remained functional [53], such provirus DNA is likely to
be replication competent, although minor modifications
in the 50-LTR may be related to reduced expression of
viral mRNA, as reported by Ebina et al. [48].
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expressed from non-integrated viral DNA of the IN-CA-de-
fective virus [54,55], whereas Vpr was shown to promote
Nef mRNA expression from such an extrachromosomal
viral DNA [56]. However, our study clearly indicated that
Vpr upregulates integration of IN-CA–defective virus into
the host genome. The positive effects of Vpr on viral trans-
duction were more prominent in MDMs than in PBMCs,
well consistent with reports that Vpr functions as a positive
factor during viral transduction into MDMs. Combined
with observations that Vpr activates ATM [36,37] and ATR
[38] and that macrophages are resistant to DSBs compared
with monocytes [20], our data suggest that the enhance-
ment of IN-CA–independent viral transduction into
MDMs may be a pivotal role of Vpr in HIV-1 infection.
In summary, our observations may have major import-
ance in the debate on the involvement of cellular factors
in viral integration. It has been postulated that DNA
damage sensor molecules are involved in the efficient
integration of viral DNA. It has also been claimed
that DNA damage sensor proteins have no involve-
ment in DNA damage-dependent viral integration.
Here we showed that DSBs are particularly important
for IN-CA–independent viral transduction and that the
effects of DSBs should be analyzed in carefully designed
experimental conditions or else their effects are obscured.
Collectively, our data suggest that complete prevention
of viral integration will require the development of
novel compounds that can protect cells from IN-
CA–independent viral integration.
Conclusion
The ATM-dependent mode of the DSB-specific viral
DNA integration and Vpr-induced DSBs may be novel
targets for anti-HIV compounds that inhibit viral trans-
duction into MDMs, which are a persistent focus of
HIV-1 infection.Methods
Plasmid constructs
The vesicular stomatitis virus glycoprotein (VSVG) expres-
sion vector pHIT/G [57], the HIV-1 proviral construct
pNL4-3 [58], pNL-ADA [59], and the HIV-1 proviral indi-
cator constructs pNL-Luc-E(−) and pNL-Luc-E(−)R(−) [37]
have been described previously. To introduce D64A muta-
tion into IN (adenine of nucleotide 4420 to cytosine) to cre-
ate pNL-IN-D64A, site-directed mutagenesis (QuikChange;
Stratagene) was performed using pNL4-3 as a template. To
create pNL-ADA-IN-D64A and pNL-Luc-IN-D64A-E(−)
that contained D64A mutants, the SpeI-PflMI fragment
(nucleotides 1507–5297) of pNL-IN-D64A was replaced
with those of pNL-ADA and pNL-Luc-E(−), respectively.
To create the Vpr-deficient construct pNL-ADA-R(−),pNL-ADA-IN-D64A-R(−), and pNL-Luc-IN-D64A-E(−)
R(−), the PflMI-SalI fragment (nucleotides 5297–5785) of
pNL-Luc-E(−)R(−) was replaced with those of pNL-
ADA, pNL-ADA-IN-D64A, and pNL-Luc-IN-D64A-
E(−), respectively.
The neomycin-resistant marker expressing vector pNL-
Neo-E(−)R(−) was created by inserting a PCR-amplified
neomycin-resistant gene into the NotI-XhoI site of pNL-
Luc-E(−)R(−). To create a neomycin-resistant marker
expressing D64A, the mutant pNL-Neo-IN-D64A-E(−)
R(−) was created by the SpeI-PflMI fragment (nucleotides
1507–5297) of pNL-IN-D64A and replaced with that of
pNL-Neo-E(−)R(−). To create pIRES2-EGFP-I-SceI, a
pIRES2-EGFP (Clontech)-based plasmid with an I-SceI
recognition site, a synthetic double-stranded oligonucleo-
tide (I-SceI-sense and I-SceI-antisense oligonucleotides;
see Additional file 1: Table S2) was inserted into the EcoRI
and BamHI sites of pIRES2-EGFP.
To make the adenoviral vector Ad-I-PpoI, I-PpoI cDNA
was amplified from pBabe-HA-ER-I-PpoI using the
Adeno-PpoI-DraI-F and Adeno-PpoI-DraI-R primers
(Additional file 1: Table S2) and cloned into the SwaI site
of the pAxCALNLwtit2 cosmid vector (NIPPON GENE).
To generate the EGFP-expressing lentiviral vector
(pLenti6-EGFP), EGFP cDNA from pENTR1a-EGFP
was cloned into pLenti6/V5-DEST (Invitrogen) using LR
Clonase (Invitrogen). The IN D64V mutation of the gag/
pol-expressing plasmid pLP1 (Invitrogen; pLP1-IN-D64V)
was introduced using pLP1 as a template with site-directed
mutagenesis (QuikChange; Stratagene).Cell culture
THP-1, HT1080, HEK293, and HEK293T cell lines were
obtained from the RIKEN Cell Bank. TIG-3 (primary
human fibroblast cells) and MT-4 cells were obtained from
the Health Science Research Resources Bank (Osaka,
Japan). HT1080, HEK293, HEK293T, MAGIC5, and TIG-3
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). MT-4 cell was maintained in RPMI 1640
supplemented with 10% FBS. To obtain macrophage-like
cells, THP-1 cells, maintained in Iscove’s modified
Dulbecco’s medium supplemented with 10% FBS, were
treated for 2 d with 5.0 × 10–8 M PMA. As described previ-
ously [60], PMA-treated THP-1 cells were positive for
Mac-1, a specific marker of macrophages. Peripheral blood
was derived from healthy donors who worked within
the institute and gave informed consent. Experimental
procedures were approved by the internal review board.
PBMCs and MDMs were prepared and cultured as previ-
ously described [61]. MDMs were prepared from healthy
volunteers who gave informed consents. The experimental
protocol was approved by the internal review board.
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The preparation and titration of replication-competent
and VSVG-pseudotyped viruses are described elsewhere
[36,37,62,63]. The lentiviral vectors were prepared using
pLenti6-EGFP and the ViraPower Lentiviral Packaging Mix
(Invitrogen) according to the manufacturer’s protocol. Viral
supernatants were centrifuged at 120 × g for 5 min, filtered
through a 0.2-μm filter, and stored at −80°C. To exchange
the medium for DMEM supplemented with 0.1% FBS, the
viruses were ultracentrifuged at 86,000 × g for 1 h.
Quantitative PCR of provirus DNA
For the quantification of early RT, late RT, 2-LTR circle,
and integrated DNA, qPCR was performed as described
elsewhere [64,65]. Briefly, cells were harvested at 48
hpi, and genomic DNA was prepared by QuickGene
(FujiFilm). For the quantification of early RT, late RT, and
2-LTR circle products, the primers and probe sets M667/
AA55/R-U5, M667/M661/R-U5, and MH535/2-LTR-AS/
NL4-3-U3 were used, respectively. TaqMan Universal
PCR Master Mix with UNG (Applied Biosystems) and
ABI7000 (Applied Biosystems) were used according to the
manufacturer’s instructions. For Alu-PCR (quantification
of integrated DNA), the primer and probe sets first-Alu-F/
first-Alu-R/first-gag-R and second-tag-R/2-LTR-S/probe-2
were used for the first and second rounds of qPCR, re-
spectively. The amplification conditions for the first round
of PCR, using AmpliTaq Gold 360 Master Mix (Applied
Biosystems), were as follows: 95°C for 10 min, followed by
12 cycles at 95°C for 15 s, 60°C for 30 s, and 72°C for 10
min. The second round of qPCR was conducted using
TaqMan Universal PCR Master Mix according to the
manufacturer’s instructions. To generate a standard curve
for Alu-PCR, HEK293T cells (approximately one million
cells) were infected with VSVG-pseudotyped NL-Luc-E(−)
R(−) virus (200 ng p24), then harvested at 30 d post-
infection (dpi), and genomic DNA was prepared. For the
quantification of β-globin DNA copy numbers, the primer
set globin-F/globin-R was used with SYBR Premix ExTaq
(TaKaRa). Sequence information for primers and probes is
listed in Additional file 1: Table S2.
Cleavage of I-SceI and I-PpoI sites
Ad-I-SceI and Ad-LacZ were prepared as described previ-
ously [36]. PMA-treated THP-1 cells were infected with
Ad-I-SceI or Ad-LacZ at 1 h post–HIV-1 infection for 1 h at
a multiplicity of infection (MOI) of 100. In Figure 1E–1H,
HT1080 cells were transfected with plasmid DNA that
encoded a chmeric protein of estrogen receptor-I-PpoI
(ER-I-PpoI), and then 4-hydroxytamoxifen (4-OHT)
was added to activate the endonuclease and induce
DSB. The pAxCALNLwtit2 cosmid vector harboring I-PpoI
cDNA was digested with BspT104I and transduced into
HEK293 cells to produce Ad-I-PpoI. The adenoviral vectorencoding Cre recombinase, AxCANCre (TaKaRa), was co-
infected with Ad-I-PpoI at an MOI of 30 to remove the
floxed stuffer between the CAG promoter and I-PpoI
cDNA.
Quantification of the I-SceI site specific viral integration
PMA-treated THP-1 cells were co-infected with WT virus
and Ad-I-SceI or Ad-LacZ, and then extracted genomic
DNA was subjected to I-SceI-qPCR analysis. I-SceI site
targeting integration rate of HIV-1 DNA was estimated
by PCR amplification using primer sets pIRES2eGFP+
543F/pNL4-3+9207R and pIRES2eGFP+574F/pNL4-3+
98R+9173R for the first and second rounds of qPCR,
respectively. The amplification conditions for the first
round of PCR, using ExTaq polymerase (TaKaRa), were as
follows: 30 cycles of 98°C for 10 s, 60°C for 30 s, and 72°C
for 30 s. The second round of qPCR was conducted using
SYBR Premix ExTaq polymerase (TaKaRa) according to the
manufacturer’s instructions. For the second round PCR
template, 1/25 the volume of the first PCR amplicon was
used. To prepare a standard sample for the I-SceI-qPCR,
the 5'-LTR DNA fragment of HIV-1 was amplified using
the pNL4-3+9074F-Sce-RI and pNL4-3+9423R-BamHI
and cloned into the EcoRI and BamHI sites of pIRES2-
EGFP (pIRES2-EGFP-5'-LTR). Then, HT1080 cells were
transfected with pIRES2-EGFP-5'-LTR and HT1080/
pIRES2-EGFP-5'-LTR cell was obtained. By Southern blot
and sequence analyses we confirmed that two copies of
the DNA fragment of pIRES2-EGFP-5'-LTR vector were
present in HT1080/pIRES2-EGFP-5'-LTR diploid cells.
Sequence information for primers and probes is listed in
Additional file 1: Table S2.
Quantification of the I-PpoI site specific viral integration
Serum starved HT1080 cells were co-infected with
Ad-I-PpoI and lentiviruses, which were generated by
pLenti6-EGFP or pLP1-IN-D64V. To estimate I-PpoI site
targeting or total integration of the lentiviral vector, I-PpoI-
qPCR or EGFP-qPCR was conducted using the TaqMan
Universal PCR Master Mix (Applied Biosystems). For I-
PpoI-qPCR in the direct or inverted repeat orientation, the
primer sets rDNA+11725R/pLenti6+5237F or rDNA+
11645F/pLenti6+5237F were used, respectively; pLenti6-
LTR was used as the TaqMan probe. For EGFP-qPCR, the
primers EGFP-F/EGFP-R and TaqMan EGFP-probe were
used. As a standard sample for estimating copy numbers of
viral DNA integrated in the I-PpoI site, genomic DNA of
HT1080/Lenti6-EGFP-std cells were was used. We have
confirmed by Southern blot and sequence analyses that
HT1080/Lenti6-EGFP-std cells harbored two copies of
Lenti6-EGFP proviral DNA in both orientations in the I-
PpoI site. On the other hand, as a standard sample for total
provirus DNA, genomic DNA of HT1080/pIRES2-EGFP-
5'-LTR cells, which possessed two copies of EGFP, were
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in Additional file 1: Table S2.PCR and sequence analysis
To amplify the host DNA/5'-LTR junction at the I-SceI site,
the primer sets pIRES2eGFP+543F/pNL4-3+9207R and
pIRES2eGFP+574F/pNL4-3+98R+9173R were used for the
first and second rounds of PCR, respectively. To amplify
the host DNA/3'-LTR junction at the I-SceI site, the primer
sets pIRES2eGFP+1910R/L-M667 and pIRES2eGFP+887R/
LambdaT were used for the first and second rounds of
PCR, respectively. The amplification conditions for the host
DNA/5'-LTR and host DNA/3'-LTR were as follows: 40
cycles for the first round of PCR or 30 cycles for the second
round of PCR at 98°C for 10 s, 60°C for 30 s, and 72°C for
30 s and 35 cycles at 98°C for 10 s, 60°C for 30 s, and 72°C
for 60 s for the first round of PCR and 30 s for the second
round of PCR, respectively. ExTaq polymerase (TaKaRa)
was used for the PCR. PCR amplicons were used directly
or cloned into pCR2.1-TOPO (Invitrogen) as a template for
sequence analysis. To amplify the rDNA/lentiviral vector at
the I-PpoI site in the direct repeat orientation, the primer
sets rDNA+11784R/pLenti6+5208F and rDNA+11747R/
pLenti6+5232F were used for the first and second rounds
of PCR, respectively. To amplify the rDNA/lentiviral vector
at the I-PpoI site in the inverted repeat orientation, the
primer sets rDNA+11589F/pLenti6+5208F and rDNA+
11612F/pLenti6+5232F were used for the first and second
rounds of PCR, respectively. The amplification conditions
for the rDNA/lentiviral vector at the I-PpoI site were as
follows: 40 cycles for the first and second rounds of PCR at
98°C for 10 s, 60°C for 30 s, and 72°C for 30 s. ExTaq
polymerase (TaKaRa) was used for PCR. PCR amplicons
were used directly or cloned into pCR2.1-TOPO
(Invitrogen) as a template for sequence analysis. To analyze
the IN mutations of NL-ADA and NL-IN-D64A-ADA
viruses in Figure 5B and 5C, viral RNAs were isolated from
conditioned medium (14 dpi; WT/RAL and D64A/DMSO,
16 dpi; D64A/RAL) and amplified by primer set pNL+
4207F/pNL+5120R and Titan One-Tube RT-PCR Kit
(Roche diagnostics). The amplicons were cloned into
pCR2.1-TOPO and sequenced. The primers are listed in
Additional file 1: Table S2.
LAM-PCR
To estimate the rate of insertion and/or deletion, the
LAM-PCR method was performed as described previously
[27,66]. Briefly, 1.0 × 106 HT1080 cells were infected with
VSVG-pseudotyped NL-Neo-E(−)R(−) virus (200 ng p24)
in the presence of RAL or DMSO, and G418-resistant
cells were harvested at 28 dpi and subjected to LAM-PCR.
The sequence information for primers is listed in
Additional file 1: Table S2.Replication assay
To evaluate the production of functional virion from
RAL-treated cells, 1 × 105 MT-4 cells were infected with
replication-competent NL4-3 or NL-IN-D64A (20 ng
p24). After 2 h of the infection, cells were washed with
phosphate buffered saline (PBS) twice and suspended in
1.0 mL of medium. To prepare the culture supernatant,
three-quarter of the cultures were harvested every 2 d,
and the culture was continued by adding 750 μL of the
complete medium into each well. From −1 dpi to har-
vest, MT-4 cells were treated with 10 μM RAL or
DMSO. Conditioned medium (100 μL) was added to 1 ×
104 MAGIC5 cells [28], and at 48 hpi, cells were stained
by X-gal to estimate the number of transduced cells. To
estimate HIV-1 RNA copy numbers, 1 × 105 MDMs
were infected with NL-ADA, NL-ADA-R(−), NL-ADA-
IN-D64A, or NL-ADA-IN-D64A-R(−) (20 ng p24) for 2
h, then washed with medium four times. Three-quarters
of the conditioned medium was harvested and replaced
with fresh medium every 2 d. From −1 dpi to harvest,
MDMs were treated with 10 μM RAL or DMSO. HIV-1
RNA of conditioned medium was purified and subjected
to RT-qPCR using the Lenti-X qRT-PCR Titration Kit
(TaKaRa). To evaluate the effect of DNA damaging
agents, 2.5 μM etoposide or 1.25 μM bleomycin were
added to MDMs from 0–2 dpi. To exclude a possibility
that detected HIV RNA merely reflect the RNA from
carry-over virion, fusion inhibitor ENF, dissolved in
phosphate buffer saline PBS, was added from 0 hpi to
harvest as a negative control.
Colony formation assay
To evaluate the effect of DNA damaging agents on the
integration rate of D64A mutant virus, serum-starved
HT1080 cells (5 × 105 cells) in DMEM with 0.1%
FBS were infected with a neomycin-resistant marker
expressing VSVG-pseudotyped NL-Neo-IN-D64A-E(−)
R(−) virus (100 ng p24) in the presence of 0 (DMSO),
0.625, 1.25, or 2.5 μM etoposide and 0 (water), 0.313,
0.625, or 1.25 μM bleomycin. Cells were selected with
G418 from 2 dpi, then stained with Giemsa at 12 dpi.
The G418-resistant colony numbers were normalized
by plating efficiency, which represented the cytotoxicity
of etoposide and bleomycin. The plating efficiencies
after treatment of etoposide and bleomycin at 0, 0.625,
1.25, 2.5 μM were 100, 57.2, 26.0 and 19.5%, and 100,
60.4, 68.8 and 60.4%, respectively.
Immunohistochemical analysis
Detection of phosphorylated histone H2AX (γH2AX) and
phosphorylated ATM (pATM) was done, according to
the reported method using antibodies against γH2AX
(phosphorylated at Ser 139, Millipore, cat no. 05–636)
and pATM (Ser 1981, Millipore, cat. no. 05–740) [37].
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4% paraformaldehyde in PBS. The fixed cells were
permeabilized with 0.2% Triton X-100 in PBS. After
treatment with PBS supplemented with 10% goat serum
for 30 min, the cells were incubated with antibodies.
After 1 h of incubation at 37°C, secondary antibodies
conjugated with Alexa 546 (Molecular Probes) were added
for 1 h at 37°C. Nuclei were stained by Hoechst33258.
Luciferase assay
To evaluate the infectivity of viruses, 1.0 × 104 cells were
infected with VSVG-pseudotyped luciferase viruses (2 ng
p24) for 48 h, then subjected to luciferase assay by using
One-Glo (Promega) and aVeritas Microplate luminometer
(TURNER BIOSYSTEMS).
Flow cytometry
To analyze the status of cell cycle, HT1080 cells were
labeled with 5 μM BrdU for 30 min and fixed in ice-cold
70% ethanol. Anti-BrdU-fluorescein (Roche Diagnostics)
was used to stain the BrdU-labeled cells, according
to the manufacturer’s instructions. BrdU-labeled cells
were analyzed by BD FACSCalibur flow cytometer (BD
Biosciences). To analyze the percentages of EGFP-
positive cells, Flow cytometry analysis was performed
using a BD FACSCalibur.FISH analysis
Metaphase FISH analysis was performed to estimate the
proviral DNA copy number and co-localization of pro-
viral DNA and rDNA using lentiviral vector and rDNA
specific probes (Chromosome Science Labo Inc.).Statistical analysis
Statistical significance was determined by Student’s t-
test, and values of P < 0.05 were considered statistically
significant.
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